» Articles » PMID: 2593166

Model Predicting Survival in Stage I Melanoma Based on Tumor Progression

Overview
Specialty Oncology
Date 1989 Dec 20
PMID 2593166
Citations 270
Authors
Affiliations
Soon will be listed here.
Abstract

We used the lesional steps in tumor progression and multivariable logistic regression to develop a prognostic model for primary, clinical stage I cutaneous melanoma. This model is 89% accurate in predicting survival. Using histologic criteria, we assigned melanomas to tumor progression steps by ascertaining their particular growth phase. These phases were the in situ and invasive radial growth phase and the vertical growth phase (the focal formation of a dermal tumor nodule or dermal tumor plaque within the radial growth phase or such dermal growth without an evident radial growth phase). After a minimum follow-up of 100.6 months and a median follow-up of 150.2 months, 122 invasive radial-growth-phase tumors were found to be without metastases. Eight-year survival among the 264 patients whose tumors had entered the vertical growth phase was 71.2%. Survival prediction in these patients was enhanced by the use of a multivariable logistic regression model. Twenty-three attributes were tested for entry into this model. Six had independently predictive prognostic information: (a) mitotic rate per square millimeter, (b) tumor-infiltrating lymphocytes, (c) tumor thickness, (d) anatomic site of primary melanoma, (e) sex of the patient, and (f) histologic regression. When mitotic rate per square millimeter, tumor-infiltrating lymphocytes, primary site, sex, and histologic regression are added to a logistic regression model containing tumor thickness alone, they are independent predictors of 8-year survival (P less than .0005).

Citing Articles

A novel dataset for nuclei and tissue segmentation in melanoma with baseline nuclei segmentation and tissue segmentation benchmarks.

Schuiveling M, Liu H, Eek D, Breimer G, Suijkerbuijk K, Blokx W Gigascience. 2025; 14.

PMID: 39970004 PMC: 11837757. DOI: 10.1093/gigascience/giaf011.


Distinct Transcriptomic and Tumor Microenvironment Profiles in Sinonasal Mucosal Melanoma and Aggressive Cutaneous Melanomas.

Molina-Garcia M, Rojas-Lechuga M, Torres Moral T, Bague J, Mateu J, Langdon C Cancers (Basel). 2025; 16(24.

PMID: 39766071 PMC: 11674703. DOI: 10.3390/cancers16244172.


Canine Adipose-Derived Mesenchymal Stromal Cells Reduce Cell Viability and Migration of Metastatic Canine Oral Melanoma Cell Lines In Vitro.

Teng F, de Faria Lainetti P, Simao Franzoni M, Fernando Leis Filho A, Massoco Salles Gomes C, Laufer-Amorim R Vet Sci. 2024; 11(12).

PMID: 39728976 PMC: 11680336. DOI: 10.3390/vetsci11120636.


Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.

PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.


Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model.

Rachunek-Medved K, Krauss S, Daigeler A, Adams C, Eckert F, Ganser K Front Immunol. 2024; 15:1501885.

PMID: 39650654 PMC: 11621216. DOI: 10.3389/fimmu.2024.1501885.